Nebivolol Krka (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, decreasing heart rate and contractility. It also stimulates nitric‑oxide release from the endothelium, causing vasodilation. The combined effect reduces peripheral resistance and lowers arterial pressure.

The dose of nebivolol is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. The prescriber determines the appropriate strength and dosing schedule; patients should follow the prescribed regimen exactly.

Nebivolol’s pregnancy category is not clearly established, and safety data are limited. It should be used only if the potential benefit justifies the potential risk to the fetus. Caution is also advised during breastfeeding, and a healthcare professional should evaluate the risk‑benefit ratio.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is a selective β1‑blocker with additional nitric‑oxide‑mediated vasodilation, which can offer better tolerability for some patients compared with non‑selective β‑blockers. Unlike ACE inhibitors or calcium‑channel blockers, its primary action is heart‑rate reduction, making it useful when a combined heart‑rate and blood‑pressure control is desired.

Nebivolol tablets should be stored at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Nebivolol is taken orally, usually once daily, with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

Serious risks include severe bradycardia, heart block, marked hypotension, and acute decompensated heart failure. Patients should be monitored for symptoms such as fainting, chest discomfort, or unusually slow heart rate, and seek medical attention promptly if these occur.

Nebivolol is contraindicated in patients with known hypersensitivity to nebivolol or any component of the formulation, in those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and in individuals with uncompensated heart failure. Caution is also advised for patients with severe asthma or chronic obstructive pulmonary disease.